期刊
EXPERT REVIEW OF HEMATOLOGY
卷 2, 期 1, 页码 17-26出版社
TAYLOR & FRANCIS LTD
DOI: 10.1586/17474086.2.1.17
关键词
acute myeloid leukemia; FLT3; internal tandem duplication; lestaurtinib; tyrosine kinase inhibitor
类别
资金
- NCI [P50 CA100632-06, R01 CA 128864]
- American Society of Clinical Oncology
Internal tandem duplication mutations of FMS-like tyrosine kinase-3 (FLT3) have been associated with poor outcomes in acute myelogenous leukemia. Over the course of the last several years, multiple agents have been developed and studied as potential inhibitors of FLT3 with the hope of providing clinical benefit for these patients. Lestaurtinib, a multi-targeted indolocarbazole derivative that potently inhibits FLT3 autophosphorylation in vitro, has been the most extensively studied agent in clinical trials to date. Multiple late-phase trials are underway to study this agent in adult and pediatric leukemia. This article will summarize the historical development of the pharmacology of lestaurtinib, as well as the ongoing investigation of the agent in preclinical and clinical studies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据